Bicycle Therapeutics (BCYC) Income from Continuing Operations (2018 - 2026)
Bicycle Therapeutics posted quarterly Income from Continuing Operations of 60825000.0 for Q1 2026, little changed year-on-year from 60909232.65 in Q1 2025, and down 126.54% on a QoQ basis from 26850000.0 in Q4 2025.
Bicycle Therapeutics (BCYC) has 9 years of Income from Continuing Operations data on file, last reported at 60825000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations changed 0.14% year-over-year to 60825000.0; the trailing twelve-month figure through Mar 2026 stood at 225727000.0 (down 856.59% YoY), and the FY2025 full-year result was 225656000.0, down 2226.02% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 60825000.0, down from 26850000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 127791000.0 in Q4 2024 and bottomed at 78952000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 39797000.0 (2024), against an average of 33835823.53.
- The widest annual swing landed in 2024, when Income from Continuing Operations surged 341.5%; it then plunged 129.1% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 32032000.0 in 2022, then tumbled by 65.19% to 52915000.0 in 2023, then soared by 341.5% to 127791000.0 in 2024, then tumbled by 121.01% to 26850000.0 in 2025, then sank by 126.54% to 60825000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 60825000.0 (Q1 2026), 26850000.0 (Q4 2025), and 59100000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Bicycle Therapeutics | 326.82 Mn | 326.82 Mn | - | -60.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.83 Mn |
| Dec 31, 2025 | -26.85 Mn |
| Sep 30, 2025 | -59.10 Mn |
| Jun 30, 2025 | -78.95 Mn |
| Mar 31, 2025 | -60.74 Mn |
| Dec 31, 2024 | 127.79 Mn |
| Sep 30, 2024 | -50.85 Mn |
| Jun 30, 2024 | -39.80 Mn |
| Mar 31, 2024 | -26.51 Mn |
| Dec 31, 2023 | -52.92 Mn |
| Sep 30, 2023 | -49.90 Mn |
| Jun 30, 2023 | -42.62 Mn |
| Mar 31, 2023 | -39.06 Mn |
| Dec 31, 2022 | -32.03 Mn |
| Sep 30, 2022 | -28.39 Mn |
| Jun 30, 2022 | -26.88 Mn |
| Mar 31, 2022 | -27.58 Mn |
| Dec 31, 2021 | -19.71 Mn |
| Sep 30, 2021 | -14.69 Mn |
| Jun 30, 2021 | -17.87 Mn |
| Mar 31, 2021 | -16.19 Mn |
| Dec 31, 2020 | -17.43 Mn |
| Sep 30, 2020 | -10.10 Mn |
| Jun 30, 2020 | -12.12 Mn |
| Mar 31, 2020 | -11.33 Mn |
| Dec 31, 2019 | -4.41 Mn |
| Sep 30, 2019 | -9.48 Mn |
| Jun 30, 2019 | -10.22 Mn |
| Mar 31, 2019 | -6.50 Mn |
| Dec 31, 2018 | -6.64 Mn |
| Sep 30, 2018 | -7.69 Mn |
| Jun 30, 2018 | -4.98 Mn |
| Mar 31, 2018 | -2.53 Mn |